The Pak1 signalling pathway in cardiac disease: from mechanistic study to therapeutic exploration

Yanwen Wang, Shunyao Wang, Ming Lei, Mark Boyett, Hoyee Tsui, Wei Liu, Xin Wang

Research output: Contribution to journalArticlepeer-review

70 Downloads (Pure)

Abstract

p21-activated kinase 1 (Pak1) is a member of the highly conserved family of serine/threonine protein kinases regulated by Ras-related small G-proteins, Cdc42/Rac1. It has been previously demonstrated to be involved in cardiac protection. Based on recent studies, this review assembles an overview of the role of Pak1 in cardiac diseases including disrupted Ca2+ homoeostasis related cardiac arrhythmias, β-adrenergic stress and pressure overload-induced hypertrophy, and ischemia/reperfusion injury. These findings demonstrate the importance of Pak1 regulation through phosphorylation and transcriptional modification of hypertrophy and/or arrhythmia-related genes. This review also discusses the anti-arrhythmic and anti-hypertrophic protective role of Pak1 and beneficial effects of FTY-720 (Fingolimod, FDA approved sphingolipid drug), a Pak1 activator in the prevention of arrhythmias and cardiac hypertrophy. These findings shed light on the therapeutic potential of Pak1 signalling in the treatment and prevention of cardiac diseases.
Original languageEnglish
JournalBritish Journal of Pharmacology
Early online date2 Jun 2017
DOIs
Publication statusPublished - 28 Jun 2017

Fingerprint

Dive into the research topics of 'The Pak1 signalling pathway in cardiac disease: from mechanistic study to therapeutic exploration'. Together they form a unique fingerprint.

Cite this